



Novel advanced test for lipoprotein size and number estimation

General Information

Description

The Liposcale® test is an advanced lipoprotein test based on nuclear magnetic resonance (NMR). From the analysis of serum or plasma samples by NMR, the concentration of cholesterol and triglycerides of the lipoprotein classes VLDL, IDL, LDL and HDL, the concentration of particles of the VLDL, LDL and HDL classes and their subclasses is obtained. large, medium and small and the size of the particles of the VLDL, LDL and HDL classes.

The software associated with the test is considered as an in vitro diagnostic medical device, and in the classification of independent software used in the health field.

Clinical practice

To properly approach CVR in patients, it is essential to correctly estimate it.

LDL-c can over- or under- estimate CHD risk in special groups such as diabetics, patients with metabolomic syndrome, etc.

Lipid lowering therapies based on LDL-P show better outcomes compared to based on LDL-C.

A more accurate approach to evaluate CVR caused by LDL can directly measure LDL-P by NMR.

Registration and Marketing Authorization

- The Liposcale® Test is an IN VITRO DIAGNOSTIC medical device that has been developed and patented complying with directive 98/79/CE (CE MARKING).
- CPT / PLA Code 0377U (USA).

Deal Design

- We are looking for a Distributor and/or Licensing Partner having a relevant sales structure in Hepatology to do a proper promotion of the Liposcale® Test.
- Deal design consisting of a Licensing Agreement to promote and market the Liposcale® Test, which serum samples will be processed in a local Central Lab with a NMR homologated by Laboratorios Rubiό, S.A.
- We are searching for the best Partners to develop trustful, fruitful and long-term business partnership.



Rubiό 55

We are pharmacypathfinders

Founded

1968

Location

Castellbisbal, Barcelona, Spain

Main Focus

CNS, Nephrology/Urology, Cardiovascular, Gastroenterology, Rheumatology/Orthopedic, Oncology/Radiotherapy, Gynecology.

About Rubiό

For 55 years Laboratorios Rubiό, a family-owned company, has been recognized for the development, manufacture and marketing of medicines with high therapeutic value for specialists as well as of certain drugs for life-threatening diseases, with long expertise in niche markets.

Laboratorios Rubiό's determination to meet the health needs of every single patient has led the company to be distinguished as per being pioneer of products targeted to low incidence diseases which affect only a small number of patients and that require the development of specific pharmaceutical products to treat them.

International Alliances and Partnering Strategy

Laboratorios Rubiό has established a strong network of partnerships through in and out activities and commercial distribution agreements. Laboratorios Rubiό has been in the export business since 1982 and has alliances in over 60 countries. Laboratorios Rubiό is constantly exploring new territories and partnerships.

Contact details:

Laboratorios Rubiό, S.A.
Industria 29, P.I. Comte de Sert
08755 Castellbisbal, Barcelona, Spain
Tel.: +34 937 722 509
Fax: +34 937 721 602
www.laboratoriosrubio.com

Contact:

afelis@labrubio.com